Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 174 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014', provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Relapsing Remitting Multiple Sclerosis (RRMS) Overview 10
Therapeutics Development 11
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview 11
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis 12
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies 13
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes 16
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies 20
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes 22
Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Sanofi 24
GlaxoSmithKline plc 25
MedImmune, LLC 26
XenoPort, Inc. 27
Novartis AG 28
Actelion Ltd 29
Mitsubishi Tanabe Pharma Corporation 30
Octapharma AG 31
Teva Pharmaceutical Industries Limited 32
Genmab A/S 33
Merck KGaA 34
Antisense Therapeutics Limited 35
Opexa Therapeutics, Inc. 36
Trophos SA 37
Allozyne, Inc. 38
Amarna Therapeutics B.V. 39
Synthetic Biologics, Inc. 40
Cognosci, Inc. 41
RedHill Biopharma Ltd. 42
Nuron Biotech, Inc. 43
Neurotec Pharma SL 44
BIOCAD 45
AbbVie Inc. 46
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
laquinimod sodium - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
alemtuzumab - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
laquinimod sodium - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
laquinimod sodium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ocrelizumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
interferon beta-1b - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
immune globulin (human) - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
daclizumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
GSK-239512 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
siponimod - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ponesimod - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
plovamer acetate - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
estriol - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
imilecleucel-t - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
olesoxime - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ATL-1102 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
vatelizumab - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
ofatumumab - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
RNS-60 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
(rifabutin + clarithromycin + clofazimine) - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
diazoxide - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
MT-1303 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
VAY-736 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
MEDI-551 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
XP-23829 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
interferon beta-1a - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
AZ-17 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Pegylated Interferon-Beta-1b - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
COG-133 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
interferon beta-1b - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
HR-411 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates 122
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 161
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products 162
Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 163
Featured News & Press Releases 163
Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 163
Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 165
Sep 11, 2014: Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE 20 mg 166
Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting 167
Jul 07, 2014: SMC Says Yes to Lemtrada (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis 167
May 27, 2014: Genzyme's Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence 168
May 27, 2014: Teva Announces Favorable European Patent Office Ruling in COPAXONE Patent Proceeding 169
May 23, 2014: Teva and Active Biotech to Continue with the Development of Nerventra for Multiple Sclerosis Following Confirmation of CHMP Opinion 170
May 15, 2014: Mylan Applauds Court's Ruling Dismissing Teva's Suit Against FDA on Copaxone 170
May 01, 2014: New TYSABRI Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients 171
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174

List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2014 11
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2014 22
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 23
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H2 2014 24
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline plc, H2 2014 25
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H2 2014 26
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by XenoPort, Inc., H2 2014 27
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H2 2014 28
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H2 2014 29
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 30
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H2 2014 31
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 32
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H2 2014 33
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H2 2014 34
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H2 2014 35
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H2 2014 36
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Trophos SA, H2 2014 37
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H2 2014 38
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H2 2014 39
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H2 2014 40
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H2 2014 41
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H2 2014 42
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Nuron Biotech, Inc., H2 2014 43
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H2 2014 44
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by BIOCAD, H2 2014 45
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H2 2014 46
Assessment by Monotherapy Products, H2 2014 47
Assessment by Combination Products, H2 2014 48
Number of Products by Stage and Target, H2 2014 51
Number of Products by Stage and Mechanism of Action, H2 2014 54
Number of Products by Stage and Route of Administration, H2 2014 56
Number of Products by Stage and Molecule Type, H2 2014 58
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H2 2014 122
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H2 2014 161
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H2 2014 162